s, and the combination
therapy was as well tolerated as Oxaliplatin treatment alone. This
study supports further evaluation of ON 01910.Na and the
combination with Oxaliplatin in additional clinical trials in
patients with liver, hormone refractory prostate and melanoma
tumors (abstract 2271).
An oral presentation, "Phase I study of ON 01910.Na, A Novel
Cell Cycle Inhibitor in Adult Patients with Solid Tumors by A.
Jimeno, J. Li, M.V.R Reddy, E.P Reddy, A. Chan, X. Zhang, P.
Kulesza, J. Wheelhouse, G. Cusatis, A. Howard, M. Maniar, W.A
Messersmith, D. Laheru, M. Rudek, S. D. Baker, M. Hidalgo, and R.
C. Donehower, summarizes the Phase I study conducted at the Sidney
Kimmel Comprehensive Cancer Center at Johns Hopkins Medical Center,
Baltimore, MD, in which ON 01910.Na has shown preliminary signs of
clinical activity early in development. ON 01910.Na has also
evidenced significant preclinical activity against a novel direct
pancreatic cancer xenograft model. A gene expression-based assay
identifies tumors likely to respond to ON 01910.Na, and will be
tested in a Phase II clinical study in pancreatic cancer patients.
Integrating early clinical and preclinical development programs is
an efficient way to generate rationale for disease-directed studies
and biomarkers (oral presentation in a "Breakthroughs in Clinical
Research" session on Monday).
Additional scientific studies employing Onconova Therapeutics,
Inc., anticancer compounds being presented at this meeting include:
"Mass Spectrometric Study of Antibody Drug conjugates" by J. Roboz,
S.Y. Cho, S. C. Bell, Glenn J. Fegley, J. L. Duke, S. C. Cosenza
and J. F. Holland (abstract 920); "Mass Spectrometric Study of Drug
Bound to Protein" by S.Y. Cho, J. Roboz, T. Ohnuma and J. F.
Holland (abstract 3182); and "Evaluation of ON 01910.Na, a novel
modulator of PLK-1 pathway and development of a cyclin B1 based
predictive assay in pancreatic cancer" by A. Jimeno, A. Chan, G.
Cusatis, X. Zhang, J. Wheelhouse, APage: 1 2 3 Related medicine technology :1
. Cell Therapeutics, Inc. Management to Discuss Todays Announcement
of Interim Pixantrone Study Results2
. Halozyme Therapeutics Enhanze Technology Large Protein Molecule
Therapeutic Clinical Trial Results Presented at the 34th Annual
Meeting of the Controlled Release Society3
. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of
Action for Ranexa4
. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into
Personalized, Cancer-Targeted Therapeutics5
. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to
Sustained Reductions in Blood Glucose Levels for 6 Months
Post-treatment in Type 2 Diabetes Patients6
. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for
Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical
. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II
Extension Trial with Tovaxin for Multiple Sclerosis8
. Orexigen Therapeutics to Present Data on Contrave Impact on
Visceral Fat and Insulin Resistance at American Diabetes
Association 67th Scientific Sessions in Chicago June 239
. Allos Therapeutics Reports Results for Phase 3 Enrich Study of
Efaproxyn in Women With Brain Metastases Originating From Breast
. Trophos Publishes ALS Article in Journal of Pharmacology and
. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase
2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care